MTOR and fatty liver disease: Furthermore, various previous studies suggested that deletion or pharmacological inhibition of IP6K ameliorates hepatic steatosis [433], which has been associated with reduced expression of markers of fatty acid uptake and lipogenesis [583] as well as augmented Akt, mTOR and GSK3β signalling in the liver [423,429,431].